Abstract
Prospective clinical trials are critical to the scientific evaluation of new treatments for brain tumors. This paper reviews basic concepts of early and late phase prospective clinical trials that are most relevant to neurosurgical oncologists, with an emphasis on the challenges associated with conducting clinical trials of brain tumor therapies. Novel clinical trial designs that meet these challenges by incorporating pretreatment “molecular profiling” and post-treatment “molecular endpoints” are described. Because of their ability to obtain brain tumor specimens from patients before and after treatment, neurosurgeons have been required to play an increasingly important role in the execution of these molecular-based clinical trials. Potential avenues for enhancing the participation of neurosurgeons in the design and development of clinical trials are discussed.
Similar content being viewed by others
References
Haines SJ: Evidence-based neurosurgery. Neurosurgery 52: 36–47, 2003
Walker MD, Green SB, Byar DP, Alexander Jr, E, Batzdorf U, Brooks WH, Hunt WE, MacCarty CS, Mahaley Jr, MS, Mealey Jr, J, Owens G, Ransohoff J, 2nd, Robertson JT, Shapiro WR, Smith Jr, KR, Wilson CB, Strike TA: Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303: 1323–329, 1980
Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin VA: A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83: 588–593, 2000
Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, Albright R, Olson J, Chang SM, O’Neill AM, Friedman AH, Bruner J, Yue N, Dugan M, Zaknoen S, Levin VA: Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 17: 2762–2771, 1999
Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, Black K, Sisti M, Brem S, Mohr G, Muller P, Morawetz R, Schold SC: Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymerbrain Tumor Treatment Group. Lancet 345: 1008–1012, 1995
Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, Whittle IR, Jaaskelainen J, Ram Z: A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU)wafers (Gliadel wafers)in patients with primary malignant glioma. Neurooncol 5: 79–88, 2003
Nazzaro JM, Neuwelt EA: The role of surgery in the management of supratentorial intermediate and high-grade astrocytomas in adults. J Neurosurg 73: 331–344, 1990
Hentschel SJ, Lang FF: Current surgical management of glioblastoma. Cancer J 9: 113–125, 2003
Lang FF, Gilbert MR, Puduvalli VK, Weinberg J, Levin VA, Yung WK, Sawaya R, Fuller GN, Conrad CA: Toward better early-phase brain tumor clinical trials: a reappraisal of current methods and proposals for future strategies. Neurooncol 4: 268–277, 2002
Chang SM, Barker FG, Schmidt MH, Sloan AE, Kasper R, Phillips L, Shih K, Hariharan S, Berger MS: Clinical Trial Participation Among Patients Enrolled in the Glioma Outcomes Project. Cancer 94: 2681–2687, 2002
Asher AL, Anderson F, Stolzenbach K, Barker F, Limentani S, Laws E: Preoperative Differences Between Community and Academic Medical Centers in the Glioma Outcomes Project. Fourth Biennial Brain Tumor Satellite Symposium, San Francisco, CA, 2000
Warnick ER, Raffel C, Glick RP: Neurooncology Research Opportunities in North America: Results of a Survey by the AANS/CNS Section on Tumors. J Neurooncol 61: 197–201, 2003
Chalmers TC: The clinical trail. Milbank Memor Fund Quart/Health Society 59: 324–339, 1981
Friedman LM, Furberg CD, DeMets DL: Introduction to Clinical Trials. In: Friedman L, Furberg C, DeMets D (eds) Fundamentals of Clinical Trials (Third Edition). Mosby-Year Book, Inc, St. Louis, 1996, pp 1–15
Friedman LM, Furberg CD, DeMets DL: Fundamentals of Clinical Trials (Third Edition). Mosby-Year Book, Inc, St Loius, 1996
Spriet A, Dupin-Spriet T, Simon P: Methodology of Clinical Drug Trials (First English Edition). S. Karger, France, 1985
Spilker B: Guide to Clinical Trials. Raven Press, New York, 1991
Ginsberg D: The Investigator’s Guide to Clinical Research. Center Watch, Inc, Boston, 1999
Cancer Therapeutic Evaluation Program Common Terminology Criteria for Adverse Events v3.0., Published December 12, 2003, http://ctep.cancer.gov, 2003
O’Quigley J, Pepe M, Fisher L: Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics 46: 33–48, 1990
Storer BE: Design and analysis of phase I clinical trials. Biometrics 45: 925–937, 1989
O’Quigley J, Chevret S: Methods for dose finding studies in cancer clinical trials: a review and results of a Monte Carlo study. Stat Med 10: 1647–1664, 1991
Armitage P: The role of randomization in clinical trials. Stat Med 1: 345–352, 1982
Byar DP, Simon RM, Friedewald WT, Schlesselman JJ, DeMets DL, Ellenberg JH, Gail MH, Ware JH: Randomized clinical trials. Perspectives on some recent ideas. N Engl J Med 295: 74–80, 1976
Pocock SJ: Allocation of patients to treatment in clinical trials. Biometrics 35: 183–197, 1979
Spilker B: Randomization procedures. In: Spilker B (ed) Guide to Clinical Trials. Raven Press, New York, 1991, pp 69–73
Freedman B: Equipoise and the ethics of clinical research. N Engl J Med 317: 141–145, 1987
Spilker B: Statistical issues. In: Spilker B (ed) Guide to Clinical Trials. Raven Press, New York, 1991, pp 497–501
Fisher L, Van Belle G: Biostatistics-A Methodology for the Health Sciences. John Wiley & Sons, New York, 1993
Crowley J: Handbook of Statistics in Clinical Oncology. Marcel Dekker, Inc, New York, 2001
Gehan EA: Methodological issues in cancer clinical trials: the comparison of therapies. Biomed Pharmacother 42: 161–165, 1988
Lachin JM: Introduction to sample size determination and power analysis for clinical trials. Control Clin Trials 2: 93–113, 1981
Davis B, Hardy R: Upper bounds for type I and type II error rates in conditional power calculations. Commun. Stat. Theor. Meth. 19: 3571–3584, 1991
Friedman L, Furberg C, DeMets DL: Sample size. In: Friedman L, Furberg C, DeMets DL (eds) Fundamentals of Clinical Trials (Third Edition). Mosby-Year Book, St. Louis, 1996, pp 94–129
Code of Federal Regulations, Title 21-Food and Drugs Revised as of April 1, 2003 U. S. Government Printing Offce Parts 50 (Protection of Human Subjects) 56 (Institutional Review Boards) 312 (Investigational New Drug Application) http://www.access.gpo.gov/cgibin/cfrassemble.cgi, 2003
The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). E6: Good Clinical Practice consolidated Guideline. http://www.ich.org/, 1996
Association of Clinical Research Professionals, Good Clinical Practices for Clinical Investigators. http://www.acrpnet.org/education/gcp/index.html, 2002
Nuremberg Code. Trials of War Criminals before the Nuremberg Military Tribunals under Control Council Law No. 10. Washington, DC, U. S. Government Printing Office, 1949, pp 181–182
World Medical Association, Declaration of Helsinki, Ethical Principals for Medical Research Involving Human Subjects. Adopted 1964, Revised 1975, 1983, 1989, 1996 http://www.wma.net/e/policy/b3.htm, 2000
The Belmont Report. Ethical Principles and Guidelines for the Protection of Human Subjects of Research. The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. http: //ohsr.od.nih.gov/mpa/belmont.php3, 1979
Food and Drug Administration Guidance for Institutional Review Boards and Clinical Investigators. http://www.fda.gov/oc/ohrt/irbs/default.htm, 1998
Gilbert MR: Brain tumor clinical trials: pitfalls and promise for the future. Curr Oncol Rep 2: 473–475, 2000
Kaplan RS: Complexities, pitfalls, and strategies for evaluating brain tumor therapies. Curr Opin Oncol 10: 175–178, 1998
Vaporciyan A, Swisher S: Thoracic Malignancies. In: Feig BW, Berger DH, Fuhrman GM (eds) The M. D. Anderson Surgical Oncology Handbook (Third Edition). Lippincott Williams & Wilkins, Philadelphia, 2003, pp 124–144
CBTRUS: Statistical Report: Primary Brain Tumors in the United States 1995–1999. Central Brain Tumor Registry of the United States, Chicago, 2002, pp 9–10
Kleihues P, Burger PC, Collins VP, Newcomb EW, Ohgaki H, Cavenee WK: Glioblastoma. In: Kleihues P, Cavenee WK (eds) Pathology & Genetics of Tumours of the Nervous System. IARC Press, Lyon, France, 2000, pp 29–39
Kim TS, Halliday AL, Hedley-Whyte ET, Convery K: Correlates of survival and the Daumas-Duport grading system for astrocytomas. J Neurosurg 74: 27–37, 1991
Gilbert MR, Supko JG, Batchelor T, Lesser G, Fisher JD, Piantadosi S, Grossman S: Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin Cancer Res 9: 2940–2949, 2003
Dowlati A, Haaga J, Remick SC, Spiro TP, Gerson SL, Liu L, Berger SJ, Berger NA, Willson JK: Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation. Clin Cancer Res 7: 2971–2976, 2001
Eisenhauer EA: Phase I and II trials of novel anti-cancer agents: endpoints, efficacy and existentialism. The Michel Clavel Lecture, held at the 10th NCI-EORTC Conference on New Drugs in Cancer Therapy, Amsterdam, 16–19 June 1998. Ann Oncol 9: 1047–1052, 1998
Gelmon KA, Eisenhauer EA, Harris AL, Ratain MJ, Workman P: Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? J Natl Cancer Inst 91: 1281–1287, 1999
Macdonald DR, Cascino TL, Schold Jr, SC, Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8: 1277–1280, 1990
Giglio P, Gilbert MR: Cerebral radiation necrosis. Neurolog 9: 180–188, 2003
Kumar AJ, Leeds NE, Fuller GN, Van Tassel P, Maor MH, Sawaya RE, Levin VA: Malignant gliomas: MR imaging spectrum of radiation therapy-and chemotherapy-induced necrosis of the brain after treatment. Radiology 217: 377–384, 2000
Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100: 57–70, 2000
Louis DN, Holland EC, Cairncross JG: Glioma classification: a molecular reappraisal. Am J Pathol 159: 779–786, 2001
Cairncross G, Macdonald D, Ludwin S, Lee D, Cascino T, Buckner J, Fulton D, Dropcho E, Stewart D, Schold C, Jr.: Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 12: 2013–2021, 1994
Lang FF, Bruner JM, Fuller GN, Aldape K, Prados MD, Chang S, Berger MS, McDermott MW, Kunwar SM, Junck LR, Chandler W, Zwiebel JA, Kaplan RS, Yung WK: Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol 21: 2508–2518, 2003
Hess KR, Wong ET, Jaeckle KA, Kyritsis AP, Levin VA, Prados MD, Yung WK: Response and progression in recurrent malignant glioma. Neurooncol 1: 282–288, 1999
Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH: Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA 91: 2076–2080, 1994
Rules and Regulations of the Joint Section on Tumors of the American Association of Neurological Surgeons and the Congress of Neurological Surgeons, 1997, pp 1–15
Solomon MJ, McLeod RS: Should we be performing more randomized controlled trials evaluating surgical operations? Surgery 118: 459–467, 1995
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lang, F.F., Asher, A. Prospective Clinical Trials of Brain Tumor Therapy: The Critical Role of Neurosurgeons. J Neurooncol 69, 151–167 (2004). https://doi.org/10.1023/B:NEON.0000041878.93045.f5
Issue Date:
DOI: https://doi.org/10.1023/B:NEON.0000041878.93045.f5